Business Wire

ORIGYN-FOUNDATION

22.4.2022 18:16:12 CEST | Business Wire | Press release

Share
ORIGYN Foundation Partners With the UEFA Foundation for Children to Premier ‘NFTs for Good’ on the Impossible Things Marketplace

ORIGYN Foundation, the Swiss non-profit foundation dedicated to identifying, authenticating and unlocking the powers of ownership for objects of value, has announced a partnership with UEFA Foundation for Children. ORIGYN and the UEFA Foundation for Children will partner to create a unique selection of collectibles and NFTs that directly benefits the foundation’s mission to fund children’s rights in areas such as health, education and integration.

As a key component of ORIGYN’s ‘NFTs for Good’ initiative, ORIGYN and UEFA Foundation for Children will create a limited collection of physical collectibles. A corresponding digital twin will be created for each of the one-of-a-kind memorabilia, including one of the toss coins that helped determine the outcome of the UEFA EURO 2020 Final between England and Italy.

“We are thrilled to partner with ORIGYN to bring these important items to the world stage and for the benefit of The UEFA Foundation for Children,” said Urs Kluser, General Secretary for the UEFA Foundation for Children. “We share a united vision of leveraging next-generation technology such as NFTs to raise money for children and world citizens across the globe. There is no better collective mission.”

ORIGYN is the only platform that ties the digital certificate to the world’s most valuable physical artifacts and collectibles. These digital twins are non-fungible, unique and, in many cases, tied to a corresponding physical object. The iconic coin will be minted by ORIGYN into a digital twin NFT and auctioned off together with the physical coin in the second quarter of 2022, alongside other rare collectibles from the foundation.

“We’re incredibly fortunate to have partnered with a foundation that shares a passion for helping children around the world. NFTs are a global technology and should benefit all,” said Daniel Haudenschild , CEO of ORIGYN Enterprise.

This series of unique sports collectibles from the UEFA Foundation for Children, as well as their corresponding digital twin NFTs, will exclusively appear on the ORIGYN-powered consumer marketplace, Impossible Things. Impossible Things will allow collectors to buy, sell and experience unique and authenticated collectibles.

The Impossible Things marketplace will launch in Q2 of 2022 with an Impossible Pass, providing holders priority access to all of the limited collection drops to appear on the marketplace.

“Leveraging ORIGYN’s proprietary technology and the unique consumer-friendly platform at Impossible Things enables us to support causes like The UEFA Foundation for Children, as well as collectors and investors who demand authenticity from the goods they purchase and the cultures that surround them,” said Tom Flanagan, Managing Director of ORIGYN Collectibles.

About the ORIGYN Foundation:

The Swiss non-profit foundation ORIGYN uses intelligent technologies, including computer vision and artificial intelligence, on decentralized computing to identify, authenticate and unlock the powers of ownership for objects of value. As the first digital certification platform built on the Internet Computer (IC), ORIGYN and its verticals generate new forms of value for some of the largest consumer asset classes in the world, including art, collectibles, digital media and luxury goods. Founded in Neuchâtel, Switzerland in October of 2020, ORIGYN operates globally in major technology and blockchain hubs around the world. The foundation’s utility token, OGY, is set to become publicly tradable in the second quarter of 2022. For more information, visit origyn.ch .

ORIGYN Foundation: Website Twitter Telegram LinkedIn Facebook Medium Instagram

For more information about Impossible Things, visit here .

About The UEFA Foundation for Children:

The UEFA Foundation for Children aims to help children and defend their rights, for example through sport and football. It provides support in the areas of health, education, access to sport, personal development, integration of minorities and employability. The Foundation, a public utility body under Swiss law, was created and started its activities on April 24, 2015. The foundation currently invests in 180 projects and has so far funded more than 400 projects in 130 countries worldwide. More than 1.8 million children have already benefited from the foundation's work since its creation.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye